Rule 8.1 - Cambridge Antibody
May 24 2006 - 4:46AM
UK Regulatory
AstraZeneca UK Limited
*T
FORM 8.1
DEALINGS BY OFFERORS, OFFEREE COMPANIES OR THEIR ASSOCIATES
FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS
(Rules 8.1(a) and (b)(i) of the City Code on Takeovers and Mergers)
1. KEY INFORMATION
Name of person dealing (Note 1) AstraZeneca UK Limited
------------------------------------------------------------------------------------------------------------------------
Company dealt in Cambridge Antibody Technology Group plc
------------------------------------------------------------------------------------------------------------------------
Class of relevant security to which the Ordinary Shares
dealings being disclosed relate (Note 2)
------------------------------------------------------------------------------------------------------------------------
Date of dealing 23 May 2006
------------------------------------------------------------------------------------------------------------------------
2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE
(a) Interests and short positions (following dealing) in the class of relevant
security dealt in (Note 3)
Long Short
------------------------------------------------------------------------------------------------------------------------
Number (%) Number (%)
------------------------------------------------------------------------------------------------------------------------
(1) Relevant securities 15,896,267(i) 29.9%
------------------------------------------------------------------------------------------------------------------------
(2) Derivatives (other than options)
------------------------------------------------------------------------------------------------------------------------
(3) Options and agreements to purchase/sell
------------------------------------------------------------------------------------------------------------------------
Total 15,896,267(i) 29.9%
------------------------------------------------------------------------------------------------------------------------
(i) This includes 1,400 ordinary shares and 200 ADSs held by Goldman, Sachs &
Co., and 76,684 shares held by Deutsche Bank AG, both of whom are deemed to be
acting in concert with AstraZeneca UK Limited, purchased prior to the
commencement of the Offer Period.
(b) Interests and short positions in relevant securities of the company, other
than the class dealt in (Note 3)
Class of relevant security: Long Short
------------------------------------------------------------------------------------------------------------------------
Number (%) Number (%)
------------------------------------------------------------------------------------------------------------------------
(1) Relevant securities
------------------------------------------------------------------------------------------------------------------------
(2) Derivatives (other than options)
------------------------------------------------------------------------------------------------------------------------
(3) Options and agreements to purchase/sell
------------------------------------------------------------------------------------------------------------------------
Total
------------------------------------------------------------------------------------------------------------------------
(c) Rights to subscribe (Note 3)
Class of relevant security: Details
------------------------------------------------------------------------------------------------------------------------
3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of securities Price per unit (Note 5)
------------------------------------------------------------------------------------------------------------------------
Purchase 5,600,000 1,320 pence
------------------------------------------------------------------------------------------------------------------------
(b) Derivatives transactions (other than options)
Product name, Long/short (Note 6) Number of securities (Note 7) Price per unit (Note 5)
e.g. CFD
------------------------------------------------------------------------------------------------------------------------
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, Number of Exercise Type, e.g. Expiry Option money
e.g. call option purchasing, securities to price American, date paid/received per
varying etc. which the option European etc. unit (Note 5)
relates (Note 7)
------------------------------------------------------------------------------------------------------------------------
(ii)Exercising
Product name, e.g. call option Number of securities Exercise price per unit (Note 5)
------------------------------------------------------------------------------------------------------------------------
(d) Other dealings (including new securities) (Note 4)
Nature of transaction (Note 8) Details Price per unit (if applicable) (Note 5)
------------------------------------------------------------------------------------------------------------------------
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
------------------------------------------------------------------------------------------------------------------------
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting
rights or future acquisition or disposal of any relevant securities to which any
derivative referred to on this form is referenced. If none, this should be
stated.
------------------------------------------------------------------------------------------------------------------------
None
------------------------------------------------------------------------------------------------------------------------
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 24 May 2006
------------------------------------------------------------------------------------------------------------------------
Contact name Keith Darlington
------------------------------------------------------------------------------------------------------------------------
Telephone number 020 7304 5000
------------------------------------------------------------------------------------------------------------------------
Name of offeree/offeror with which associated AstraZeneca UK Limited
------------------------------------------------------------------------------------------------------------------------
Specify category and nature of associate status (Note 10) Offeror
------------------------------------------------------------------------------------------------------------------------
Notes
The Notes on Form 8.1 can be viewed on the Takeover Panel's website at
www.thetakeoverpanel.org.uk
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Jul 2023 to Jul 2024
